JP MORGAN/CALL/VERTEX PHARMACEUTICALS/410/0.1/17.01.25

JP MORGAN/CALL/VERTEX PHARMACEUTICALS/410/0.1/17.01.25 Share Price

DE000JL1Z9L0

Market Closed - Bid/Ask 09:56:46 20/06/2024 BST			Pre-market 07:00:16
8.06 ^EUR	+1.13%		8.61	+6.82%

Current month	+22.68%
1 month	+17.32%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart JP MORGAN/CALL/VERTEX PHARMACEUTICALS/410/0.1/17.01.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex Pharmaceuticals Has Pricing Accord for Cystic Fibrosis Drugs With UK National Health Service	06-20	MT
Vertex Announces Extended Long-Term Reimbursement Agreement with NHS England for Access to Cystic Fibrosis Medicines KAFTRIO®, SYMKEVI® and ORKAMBI®	06-20	BU
Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465	06-17	MT
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials	06-14	MT

More news

Quotes 5-day view

Date	Price	Change
20/06/24	8.06	+1.13%
19/06/24	7.97	-6.89%
18/06/24	8.56	-5.20%
17/06/24	9.03	+3.56%
14/06/24	8.72	+2.23%

Delayed Quote Börse Stuttgart

Last update June 20, 2024 at 09:56 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	J.P. Morgan
WKN	JL1Z9L
ISIN	DE000JL1Z9L0
Date issued	17/04/2023
Strike	410 $
Maturity	17/01/2025 (211 Days)
Parity	10 : 1
Emission price	3.39 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	9.49 €
Lowest since issue	3.02 €
Delta	0.79x
Omega	4.079
Premium	6.28x
Gearing	5.18x
Moneyness	1.150
Difference Strike	-61.38 $
Difference Strike %	-14.97%
Spread	0.3 €
Spread %	3.47%
Theoretical value	8.610
Implied Volatility	35.13 %
Total Loss Probability	30.50 %
Intrinsic value	5.726
Present value	2.884
Break even	502.29 €
Theta	-0.09x
Vega	0.1x
Rho	0.15x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

471.4 USD

Average target price

463.4 USD

Spread / Average Target

-1.69%

Consensus